Navigation Links
Topokine Announces Dosing of First Subject in a Phase I Clinical Trial of XAF5 Gel for Local Reduction of Subcutaneous Fat
Date:12/5/2012

Newton, MA (PRWEB) December 05, 2012

Topokine Therapeutics has announced that the first subject has been dosed in a repeat-dose, healthy volunteer study of XAF5 Gel, a skin cream for local reduction of excess subcutaneous fat (lipohypertrophy). The study is assessing the safety and tolerability of repeat doses of XAF5 Gel at three concentrations. The study is also quantifying the effects of XAF5 on subcutaneous adipose tissue.

“We are excited to enter clinical development with the first non-invasive, local drug therapy to reduce lipohypertrophy,” said Topokine’s Chief Scientific Officer, Michael Singer, MD, PhD. “We hope to provide a convenient and effective alternative to surgery and injections.”

XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors. XAF5 reduces adipose tissue in vivo without inflammation or necrosis.

“Topokine’s preclinical data are promising,” said Jeffrey S. Dover, MD, FRCPC, a nationally recognized dermatologist and member of the Company’s Scientific Board of Advisors. “A skin cream that reduces subcutaneous fat would be an attractive proposition for patients and physicians alike.”

The company expects to report top-line results in the first half of 2013.

About Topokine and XAF5 Gel
Topokine Therapeutics is a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics. The company's lead program, XAF5 Gel, is a skin cream being developed for local reduction of excess subcutaneous fat. XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors. XAF5 reduces adipose tissue in vivo without inflammation or necrosis.

Forward-Looking Statements
This press release contains forward-looking statements regarding the development of XAF5. These statements are based on Topokine’s current beliefs and expectations, but actual results may differ.

Read the full story at http://www.prweb.com/releases/2012/12/prweb10203404.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Biocartis Announces Commercial Launch of a New Biomarker Analysis Platform
2. Chemical Publishing Company Announces its Niche Catalog in the Water Technology and Water Treatment Space
3. Japan Bioinformatics Announces Study on Leading Mapping Tools for DNA Mutation Discovery
4. The Scientist Proudly Announces the Top 10 Innovations of 2012
5. Bayer CropScience Announces LibertyLink LinkUp Offer Increased for 2013 Season
6. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
7. Genomic Health Announces Presentation of Six Studies at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium
8. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
9. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
10. Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinsons Disease
11. BioRestorative Therapies Announces Launch of New Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Parallel 6 , the leading software as a ... Reach Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine ... team. , Using the CONSULT module, patients and physicians can schedule a face to ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, ... faculty of the University of North Carolina Kenan-Flagler Business School effective ... at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology:
(Date:6/2/2016)... -- Perimeter Surveillance & Detection Systems, Biometrics ... Support & Other Service  The latest report ... analysis of the global Border Security market . ... $17.98 billion in 2016. Now: In November ... software and hardware technologies for advanced video surveillance. ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
Breaking Biology News(10 mins):